Delivery Order SPE2DB22D2005-SPE2DB25FJSB5
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Cyclosporine 0.05% Eye Emulsion in 30-unit quantities, with a ceiling value of $6,435.48 and a firm fixed price structure. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global...
- The Defense Logistics Agency awarded a $1,342.35 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Cyclosporine 0.05% Eye Emulsion (30-count units). This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The contract specifies a place of performance in Conshohocken, Pennsylvania, AmerisourceBergen's corporate headquarters, with an ultimate completion date of July 25, 2025. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Cyclosporine 0.05% Eye Emulsion (30 count) with a ceiling value of $2,072.32. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is classified as a delivery order, with an ultimate completion date of August 19, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This...
- The Defense Logistics Agency awarded a $1,216.72 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Cyclosporine 0.05% Eye Emulsion in 60-unit packaging. This is a firm fixed-price delivery order with an ultimate completion date of July 24, 2025, utilizing no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement needs. The...
- The Defense Logistics Agency awarded a delivery order valued at $1,307.00 to AmerisourceBergen Drug Corp for Cyclosporine 0.05% Eye Emulsion (60 single-use containers) on August 11, 2025, with an ultimate completion date of August 12, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued competitively under AmerisourceBergen's larger prime contract vehicle. The pharmaceutical will be delivered to the company's distribution facility in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $6,553.50 to AmerisourceBergen Drug Corp for the supply of Cyclosporine 0.05% Eye Emulsion in 30-unit quantities. This is a firm fixed price, competitively awarded delivery order with an ultimate completion date of August 26, 2025, issued on August 25, 2025. The contract involves no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Cyclosporine 0.05% Eye Emulsion in 30-unit quantities, valued at $1,068.57. This contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The order is scheduled for ultimate completion by July 21, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Cyclosporine 0.05% Eye Emulsion in 30-count units, valued at $3,558.39. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award eligibility. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of July 23, 2025. This delivery order represents a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Cyclosporine 0.05% Eye Emulsion (30 count) with a ceiling value of $1,381.69. This firm fixed-price delivery order, with an ultimate completion date of August 26, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The award was not...
- The Defense Logistics Agency awarded a $7,327.31 delivery order to AmerisourceBergen Drug Corp for Cyclosporine 0.05% Eye Emulsion (30-count packages) on July 21, 2025, with completion scheduled for July 22, 2025. This firm fixed-price delivery order, which carries no set-aside designation, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical supply transaction under the company's broader federal medical...
- SPE2DB22D2005Indefinite Delivery Contract
- SPE2DB22D2005-SPE2DB25FJSB5Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,834.62 to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Cyclosporine 0.05% Eye Emulsion in 30-unit quantities. The contract is classified as a firm fixed price delivery order with an ultimate completion date of August 20, 2025, and represents a non-competitive set-aside procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems through the DLA Medical Supply Chain. The company's extensive federal contract portfolio demonstrates its capability to supply a wide range of pharmaceutical products, medical devices, and specialized healthcare commodities across multiple therapeutic domains. This delivery order for Cyclosporine, an immunosuppressant medication commonly used in ophthalmology, exemplifies the company's role in fulfilling the Defense Health Agency's medical supply requirements through the broader DLA prime vendor program infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.8k | 8/19/25 |